Lifevantage Corp LFVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
7/9
Piotroski F — financial health
-0.45
Altman Z″ — distress risk · distress
21.1%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $228.5M | $9.8M | $183.7M | $10.5M | $34.6M |
| 2024 | $200.2M | $2.9M | $158.7M | $10.0M | $26.0M |
| 2023 | $213.4M | $2.5M | $170.0M | $3.8M | $34.6M |
| 2022 | $206.4M | $3.1M | $168.3M | $6.4M | $31.5M |
| 2021 | $220.2M | $12.9M | $182.0M | $12.5M | $36.8M |
| 2020 | $232.9M | $11.5M | $195.0M | $15.6M | $33.3M |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.45 (distress)
- Working capital / assets 0.329
- Retained earnings / assets -1.447
- EBIT / assets 0.17
- Equity / liabilities 0.928
Source: SEC EDGAR filings · CIK 0000849146 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.